You are here: Industry Insights > Gimsilumab

News List

Roivant Releases Gimsilumab Trial Updates for ARDS Prevention, Treatment for COVID-19 Patients americanpharmaceuticalreview
May 20, 2020
Roivant Sciences announced several updates for its adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal BREATHE trial ...
Roivant Doses First Patient in Gimsilumab Trial for COVID-19 Acute Respiratory Distress Syndrome Prevention americanpharmaceuticalreview
April 17, 2020
Roivant Sciences announced the first patient was dosed at Temple University Hospital in Philadelphia in an adaptive, randomized, double-blind, placebo-controlled ...
Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome prnewswire
April 16, 2020
Roivant Sciences announced that the first patient was dosed at Temple University Hospital in Philadelphia in an adaptive, randomized, double-blind, placebo-controlled ...
Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19 americanpharmaceuticalreview
April 01, 2020
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF).
Altasciences Completes Phase I Study in COVID-19 Patients contractpharma
March 30, 2020
Gimsilumab, a monoclonal antibody, is being evaluated in patients with or at risk of developing acute respiratory distress syndrome.
Roivant Develops Gimsilumab for ARDS Associated with COVID-19 americanpharmaceuticalreview
March 23, 2020
Roivant Sciences has engaged with regulators in the United States, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment ...
Roivant, Mateon to develop Covid-19 drug candidates pharmaceutical-technology
March 20, 2020
Roivant Sciences is in discussion with the US, Europe and Asian regulators to develop gimsilumab for treating acute respiratory distress syndrome (ARDS) caused by Covid-19.